Financial Performance - The company's operating revenue for Q1 2022 was ¥166,716,293.63, representing a significant increase of 335.76% compared to the same period last year[3]. - The net profit attributable to shareholders was a loss of ¥22,955,758.38, a decrease of 928.87% year-over-year[3]. - The net cash flow from operating activities was negative at ¥87,572,135.13, reflecting a decline of 2,358.94% compared to the previous year[3]. - Basic and diluted earnings per share were both -¥0.0335, a decrease of 937.50% year-over-year[3]. - The net loss for Q1 2022 was ¥27.90 million, compared to a net profit of ¥0.56 million in Q1 2021, indicating a shift in financial performance[15][16]. - The company's gross profit margin for Q1 2022 was approximately -23.8%, down from a positive margin in the previous year[15]. - The company reported a total comprehensive loss of ¥27.71 million for Q1 2022, compared to a comprehensive income of ¥0.70 million in Q1 2021[16]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,290,453,763.98, down 5.04% from the previous year[3]. - Current assets totaled CNY 302,815,704.36, slightly up from CNY 302,056,104.92, indicating a marginal increase of about 0.25%[12]. - The company's long-term equity investments amounted to CNY 661,462,128.88, up from CNY 652,016,329.76, showing a growth of about 1.5%[12]. - Total liabilities as of Q1 2022 amounted to ¥2.27 billion, slightly up from ¥2.24 billion in the previous year[13]. - Total liabilities amounted to approximately 2.24 billion, with current liabilities at about 1.08 billion and non-current liabilities at approximately 1.16 billion[23]. Shareholders' Equity - Shareholders' equity attributable to the company decreased by 19.74% to ¥733,166,573.12 compared to the end of the previous year[3]. - The equity attributable to shareholders of the parent company decreased to ¥733.17 million in Q1 2022 from ¥913.44 million in Q1 2021[13]. - Shareholders' equity totaled approximately 1.22 billion, with equity attributable to the parent company at around 913.44 million[23]. Cash Flow - Cash inflow from operating activities in Q1 2022 was CNY 162,513,832.34, a significant increase from CNY 54,092,705.02 in Q1 2021, representing a growth of 200.5%[19]. - Net cash outflow from operating activities in Q1 2022 was CNY -87,572,135.13, compared to a positive cash flow of CNY 3,876,689.24 in Q1 2021[19]. - Cash inflow from financing activities in Q1 2022 totaled CNY 153,980,498.05, up from CNY 109,000,000.00 in Q1 2021, marking an increase of 41.2%[20]. - The ending cash and cash equivalents balance as of Q1 2022 was CNY 26,318,342.47, down from CNY 285,423,416.09 at the end of Q1 2021[20]. Research and Development - Research and development expenses increased by 781.01% due to higher investment in R&D activities by the subsidiary[5]. - Research and development expenses increased to ¥6.94 million in Q1 2022, compared to ¥0.79 million in Q1 2021, reflecting a focus on innovation[15]. Inventory and Receivables - The company reported a significant increase in inventory by 63.71% due to reclassification of trial production products[5]. - Accounts receivable increased to CNY 23,538,868.48 from CNY 19,526,701.88, marking an increase of about 20.5%[11]. - Inventory rose significantly to CNY 159,970,089.39 from CNY 97,714,459.00, reflecting an increase of approximately 63.6%[11]. Government Subsidies and Adjustments - The company received government subsidies amounting to ¥2,349,969.04 related to the elimination of outdated production capacity[4]. - The company made retrospective adjustments to revenue and costs related to the sale of products generated during the trial production of the month桂二酸 project[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,498[6]. - The company has no significant related party transactions among the top shareholders, ensuring independent operations[9]. - The company has not reported any significant new strategies or product developments during the quarter[10].
宁科生物(600165) - 2022 Q1 - 季度财报